Smith & Nephew (LON:SN) Given Hold Rating at Berenberg Bank

Berenberg Bank reaffirmed their hold rating on shares of Smith & Nephew (LON:SN) in a research note published on Friday, Marketbeat.com reports. Berenberg Bank currently has a GBX 13 target price on the stock.

Separately, Royal Bank Of Canada restated a “sector perform” rating and set a GBX 1,350 price objective on shares of Smith & Nephew in a research note on Tuesday, March 17th. Two investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of GBX 1,166.83.

Smith & Nephew Price Performance

SN traded up GBX 10 during trading hours on Friday, hitting GBX 1,147. 1,316,259 shares of the stock were exchanged, compared to its average volume of 343,671. The stock has a 50 day simple moving average of GBX 1,243.05 and a 200-day simple moving average of GBX 1,261.38. The firm has a market capitalization of £12.57 billion, a PE ratio of 41.30, a price-to-earnings-growth ratio of 0.46 and a beta of 0.74. The company has a debt-to-equity ratio of 62.90, a quick ratio of 0.84 and a current ratio of 2.57.

About Smith & Nephew

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.